Oncology Institute (TOI) Competitors

$5.28 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$5.34 +0.06 (+1.23%)

As of 07/2/2026 07:29 PM Eastern

TOI vs. WGS, SNDA, VRDN, ADUS, and AVAH

Should you buy Oncology Institute stock or one of its competitors? MarketBeat compares Oncology Institute with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oncology Institute include GeneDx (WGS), Sonida Senior Living (SNDA), Viridian Therapeutics (VRDN), Addus HomeCare (ADUS), and Aveanna Healthcare (AVAH). These companies are all part of the "healthcare" industry.

How does Oncology Institute compare to GeneDx?

GeneDx (NASDAQ:WGS) and Oncology Institute (NASDAQ:TOI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

GeneDx presently has a consensus price target of $87.43, indicating a potential upside of 29.50%. Oncology Institute has a consensus price target of $7.75, indicating a potential upside of 46.78%. Given Oncology Institute's stronger consensus rating and higher probable upside, analysts plainly believe Oncology Institute is more favorable than GeneDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

61.7% of GeneDx shares are held by institutional investors. Comparatively, 36.9% of Oncology Institute shares are held by institutional investors. 25.2% of GeneDx shares are held by insiders. Comparatively, 4.4% of Oncology Institute shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, GeneDx had 33 more articles in the media than Oncology Institute. MarketBeat recorded 33 mentions for GeneDx and 0 mentions for Oncology Institute. Oncology Institute's average media sentiment score of 1.00 beat GeneDx's score of 0.09 indicating that Oncology Institute is being referred to more favorably in the news media.

Company	Overall Sentiment
GeneDx	Neutral
Oncology Institute	Positive

Oncology Institute has a net margin of -7.42% compared to GeneDx's net margin of -17.58%. GeneDx's return on equity of 9.15% beat Oncology Institute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-17.58%	9.15%	5.21%
Oncology Institute	-7.42%	N/A	-24.68%

GeneDx has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market. Comparatively, Oncology Institute has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market.

GeneDx has higher earnings, but lower revenue than Oncology Institute. GeneDx is trading at a lower price-to-earnings ratio than Oncology Institute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54M	4.69	-$21.02M	-$2.68	N/A
Oncology Institute	$502.73M	1.04	-$60.61M	-$0.37	N/A

Summary

GeneDx beats Oncology Institute on 9 of the 16 factors compared between the two stocks.

How does Oncology Institute compare to Sonida Senior Living?

Oncology Institute (NASDAQ:TOI) and Sonida Senior Living (NYSE:SNDA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

In the previous week, Sonida Senior Living had 1 more articles in the media than Oncology Institute. MarketBeat recorded 1 mentions for Sonida Senior Living and 0 mentions for Oncology Institute. Oncology Institute's average media sentiment score of 1.00 beat Sonida Senior Living's score of 0.00 indicating that Oncology Institute is being referred to more favorably in the media.

Company	Overall Sentiment
Oncology Institute	Positive
Sonida Senior Living	Neutral

Oncology Institute has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market. Comparatively, Sonida Senior Living has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market.

Oncology Institute has a net margin of -7.42% compared to Sonida Senior Living's net margin of -24.15%. Oncology Institute's return on equity of 0.00% beat Sonida Senior Living's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-7.42%	N/A	-24.68%
Sonida Senior Living	-24.15%	-36.98%	-7.08%

Oncology Institute has higher revenue and earnings than Sonida Senior Living. Oncology Institute is trading at a lower price-to-earnings ratio than Sonida Senior Living, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$502.73M	1.04	-$60.61M	-$0.37	N/A
Sonida Senior Living	$381.14M	5.23	-$70.78M	-$5.83	N/A

36.9% of Oncology Institute shares are owned by institutional investors. Comparatively, 87.6% of Sonida Senior Living shares are owned by institutional investors. 4.4% of Oncology Institute shares are owned by insiders. Comparatively, 39.3% of Sonida Senior Living shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Oncology Institute currently has a consensus target price of $7.75, indicating a potential upside of 46.78%. Sonida Senior Living has a consensus target price of $41.25, indicating a potential downside of 2.01%. Given Oncology Institute's stronger consensus rating and higher possible upside, analysts plainly believe Oncology Institute is more favorable than Sonida Senior Living.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Sonida Senior Living	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Oncology Institute beats Sonida Senior Living on 9 of the 16 factors compared between the two stocks.

How does Oncology Institute compare to Viridian Therapeutics?

Viridian Therapeutics (NASDAQ:VRDN) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

In the previous week, Viridian Therapeutics had 8 more articles in the media than Oncology Institute. MarketBeat recorded 8 mentions for Viridian Therapeutics and 0 mentions for Oncology Institute. Viridian Therapeutics' average media sentiment score of 1.05 beat Oncology Institute's score of 1.00 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Viridian Therapeutics	Positive
Oncology Institute	Positive

Oncology Institute has a net margin of -7.42% compared to Viridian Therapeutics' net margin of -490.31%. Oncology Institute's return on equity of 0.00% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-490.31%	-80.19%	-48.84%
Oncology Institute	-7.42%	N/A	-24.68%

Viridian Therapeutics presently has a consensus price target of $38.79, suggesting a potential upside of 99.93%. Oncology Institute has a consensus price target of $7.75, suggesting a potential upside of 46.78%. Given Viridian Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Viridian Therapeutics is more favorable than Oncology Institute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Oncology Institute has higher revenue and earnings than Viridian Therapeutics. Oncology Institute is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85M	28.22	-$342.60M	-$3.32	N/A
Oncology Institute	$502.73M	1.04	-$60.61M	-$0.37	N/A

36.9% of Oncology Institute shares are owned by institutional investors. 2.4% of Viridian Therapeutics shares are owned by insiders. Comparatively, 4.4% of Oncology Institute shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Viridian Therapeutics has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Oncology Institute has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market.

Summary

Viridian Therapeutics and Oncology Institute tied by winning 8 of the 16 factors compared between the two stocks.

How does Oncology Institute compare to Addus HomeCare?

Addus HomeCare (NASDAQ:ADUS) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Addus HomeCare has higher revenue and earnings than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addus HomeCare	$1.45B	1.36	$95.91M	$5.41	19.44
Oncology Institute	$502.73M	1.04	-$60.61M	-$0.37	N/A

Addus HomeCare presently has a consensus price target of $131.00, indicating a potential upside of 24.56%. Oncology Institute has a consensus price target of $7.75, indicating a potential upside of 46.78%. Given Oncology Institute's higher possible upside, analysts plainly believe Oncology Institute is more favorable than Addus HomeCare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addus HomeCare	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Addus HomeCare had 2 more articles in the media than Oncology Institute. MarketBeat recorded 2 mentions for Addus HomeCare and 0 mentions for Oncology Institute. Oncology Institute's average media sentiment score of 1.00 beat Addus HomeCare's score of 0.93 indicating that Oncology Institute is being referred to more favorably in the news media.

Company	Overall Sentiment
Addus HomeCare	Positive
Oncology Institute	Positive

95.3% of Addus HomeCare shares are owned by institutional investors. Comparatively, 36.9% of Oncology Institute shares are owned by institutional investors. 4.1% of Addus HomeCare shares are owned by insiders. Comparatively, 4.4% of Oncology Institute shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Addus HomeCare has a net margin of 6.89% compared to Oncology Institute's net margin of -7.42%. Addus HomeCare's return on equity of 9.80% beat Oncology Institute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addus HomeCare	6.89%	9.80%	7.34%
Oncology Institute	-7.42%	N/A	-24.68%

Addus HomeCare has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Oncology Institute has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market.

Summary

Addus HomeCare beats Oncology Institute on 14 of the 17 factors compared between the two stocks.

How does Oncology Institute compare to Aveanna Healthcare?

Oncology Institute (NASDAQ:TOI) and Aveanna Healthcare (NASDAQ:AVAH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

Oncology Institute presently has a consensus target price of $7.75, suggesting a potential upside of 46.78%. Aveanna Healthcare has a consensus target price of $10.50, suggesting a potential upside of 15.38%. Given Oncology Institute's higher possible upside, equities research analysts plainly believe Oncology Institute is more favorable than Aveanna Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Aveanna Healthcare	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.67

Aveanna Healthcare has higher revenue and earnings than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than Aveanna Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$502.73M	1.04	-$60.61M	-$0.37	N/A
Aveanna Healthcare	$2.43B	0.81	$225.03M	$1.18	7.71

Aveanna Healthcare has a net margin of 10.37% compared to Oncology Institute's net margin of -7.42%. Aveanna Healthcare's return on equity of 124.68% beat Oncology Institute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-7.42%	N/A	-24.68%
Aveanna Healthcare	10.37%	124.68%	7.07%

Oncology Institute has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market. Comparatively, Aveanna Healthcare has a beta of 1.89, meaning that its share price is 89% more volatile than the broader market.

36.9% of Oncology Institute shares are owned by institutional investors. Comparatively, 88.0% of Aveanna Healthcare shares are owned by institutional investors. 4.4% of Oncology Institute shares are owned by insiders. Comparatively, 5.3% of Aveanna Healthcare shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Aveanna Healthcare had 9 more articles in the media than Oncology Institute. MarketBeat recorded 9 mentions for Aveanna Healthcare and 0 mentions for Oncology Institute. Oncology Institute's average media sentiment score of 1.00 beat Aveanna Healthcare's score of 0.47 indicating that Oncology Institute is being referred to more favorably in the media.

Company	Overall Sentiment
Oncology Institute	Positive
Aveanna Healthcare	Neutral

Summary

Aveanna Healthcare beats Oncology Institute on 14 of the 17 factors compared between the two stocks.

Get Oncology Institute News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TOI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TOI vs. The Competition

Export

Metric	Oncology Institute	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$521.87M	$9.63B	$7.16B	$12.48B
Dividend Yield	N/A	1.62%	2.66%	6.52%
P/E Ratio	-14.27	27.84	28.02	24.70
Price / Sales	1.04	18.50	540.37	99.49
Price / Cash	N/A	114.69	49.26	57.09
Price / Book	-33.00	6.19	10.96	6.46
Net Income	-$60.61M	$179.69M	$3.57B	$337.01M
7 Day Performance	-2.04%	3.82%	2.12%	1.69%
1 Month Performance	8.42%	10.36%	5.25%	3.81%
1 Year Performance	114.20%	14.53%	33.29%	23.90%

Oncology Institute Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TOI Oncology Institute	3.8386 of 5 stars	$5.28 flat	$7.75 +46.8%	+114.2%	$521.87M	$502.73M	N/A	660	Positive News
WGS GeneDx	3.968 of 5 stars	$68.65 -0.7%	$87.43 +27.4%	-26.3%	$2.04B	$442.68M	N/A	1,300	Trending News Gap Up
SNDA Sonida Senior Living	1.1765 of 5 stars	$40.79 +2.8%	$41.25 +1.1%	N/A	$1.93B	$411.85M	N/A	5,140	High Trading Volume
VRDN Viridian Therapeutics	3.9542 of 5 stars	$18.37 -2.2%	$38.79 +111.1%	+24.5%	$1.89B	$70.92M	N/A	50	Positive News Analyst Forecast Gap Down
ADUS Addus HomeCare	4.1623 of 5 stars	$100.47 +2.5%	$131.00 +30.4%	-6.0%	$1.88B	$1.42B	18.57	50,659	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TOI) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncology Institute (TOI) Competitors

TOI vs. WGS, SNDA, VRDN, ADUS, and AVAH

How does Oncology Institute compare to GeneDx?

Summary

How does Oncology Institute compare to Sonida Senior Living?

Summary

How does Oncology Institute compare to Viridian Therapeutics?

Summary

How does Oncology Institute compare to Addus HomeCare?

Summary

How does Oncology Institute compare to Aveanna Healthcare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TOI vs. The Competition

Oncology Institute Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncology Institute (TOI) Competitors

TOI vs. WGS, SNDA, VRDN, ADUS, and AVAH

How does Oncology Institute compare to GeneDx?

Do analysts rate WGS or TOI?

Do insiders and institutionals believe in WGS or TOI?

Does the media prefer WGS or TOI?

Is WGS or TOI more profitable?

Which has more volatility & risk, WGS or TOI?

Which has better earnings & valuation, WGS or TOI?

Summary

How does Oncology Institute compare to Sonida Senior Living?

Does the media refer more to TOI or SNDA?

Which has more volatility & risk, TOI or SNDA?

Is TOI or SNDA more profitable?

Which has preferable valuation and earnings, TOI or SNDA?

Do insiders & institutionals have more ownership in TOI or SNDA?

Do analysts prefer TOI or SNDA?

Summary

How does Oncology Institute compare to Viridian Therapeutics?

Does the media prefer VRDN or TOI?

Is VRDN or TOI more profitable?

Do analysts rate VRDN or TOI?

Which has stronger valuation & earnings, VRDN or TOI?

Do insiders & institutionals have more ownership in VRDN or TOI?

Which has more risk & volatility, VRDN or TOI?

Summary

How does Oncology Institute compare to Addus HomeCare?

Which has stronger valuation and earnings, ADUS or TOI?

Do analysts prefer ADUS or TOI?

Does the media prefer ADUS or TOI?

Do insiders and institutionals have more ownership in ADUS or TOI?

Is ADUS or TOI more profitable?

Which has more volatility and risk, ADUS or TOI?

Summary

How does Oncology Institute compare to Aveanna Healthcare?

Do analysts prefer TOI or AVAH?

Which has better valuation and earnings, TOI or AVAH?

Is TOI or AVAH more profitable?

Which has more volatility and risk, TOI or AVAH?

Do institutionals & insiders hold more shares of TOI or AVAH?

Does the media refer more to TOI or AVAH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TOI vs. The Competition

Oncology Institute Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools